TNOX Tanox (MM)

HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) will report its 2006 third quarter financial results Nov. 2, 2006. The announcement will be made prior to market open, with a conference call for the investment community to follow at 10 a.m., EST. Tanox President and Chief Executive Officer Danong Chen, Ph.D. and Vice President of Finance Greg Guidroz will summarize the quarter results and provide an update on the company's operations and drug-development pipeline. A question-and-answer session will follow their remarks. Live audio of the conference call will be simultaneously webcast on the Internet. The webcast will be accessible from the Tanox Web site at http://www.tanox.com/ in the Investor Relations section. About Tanox, Inc. Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and is approved for marketing in the United States, Canada and major European countries. Tanox is based in Houston and has a manufacturing facility in San Diego. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright